← FDA DRUG APPROVALS

FDA ANDA · ANDA201821

CLINDAMYCIN PALMITATE HYDROCHLORIDE (PEDIATRIC)

clindamycin palmitate hydrochloride

Sponsor: RISING

APPLICATION
ANDA201821
TYPE
ANDA
ORIGINAL APPROVAL
2012-08-28
LATEST ACTION
2022-08-22
ROUTE
ORAL
DOSAGE FORM
FOR SOLUTION
MARKETING STATUS
Prescription

Products

CLINDAMYCIN PALMITATE HYDROCHLORIDEPrescription
CLINDAMYCIN PALMITATE HYDROCHLORIDE EQ 75MG BASE/5ML · FOR SOLUTION · ORAL

Approval history

2022-08-22Labeling · Supplement 5 · standardAP
2022-08-22Labeling · Supplement 3 · standardAP
2012-08-28Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →